ATTR amyloidosis

FDA denies expanded approval for Alnylam RNA drug
BioPharma Dive
Mon, 10/9/23 - 10:15 am
Alnylam
FDA
RNA
Patisiran
ATTR amyloidosis
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Motley Fool
Wed, 04/19/23 - 10:26 am
AstraZeneca
Ionis Pharmaceuticals
eplontersen
ATTR amyloidosis
Intellia's Latest Data Indicate Full Potential of CRISPR
BioSpace
Sun, 09/18/22 - 10:31 pm
Intellia Therapeutics
ATTR amyloidosis
hereditary angiodema
CRISPR
Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential
Fierce Biotech
Fri, 09/16/22 - 10:53 am
Intellia Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
clinical trials
Regeneron
Alnylam shoots for the heart
EP Vantage
Thu, 05/19/22 - 10:16 am
Alnylam
Onpattro
ATTR amyloidosis
Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report
Fierce Biotech
Mon, 10/25/21 - 11:53 pm
Intellia Therapeutics
LogicBio Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion
Fierce Biotech
Mon, 07/12/21 - 10:40 am
Novo Nordisk
Prothena
ATTR amyloidosis
PRX004
Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing
Fierce Biotech
Thu, 01/7/21 - 11:33 am
clinical trials
Alnylam
ATTR amyloidosis
vutrisiran
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Pfizer
tafamidis
FDA
Vyndaqel
Alnylam
Ionis
ATTR amyloidosis
Alnylam Pharmaceuticals Is Launched and Ready for More
Motley Fool
Tue, 02/12/19 - 11:32 am
Alnylam
ATTR amyloidosis
Onpattro
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
Motley Fool
Tue, 08/28/18 - 10:18 am
Alnylam
Onpattro
Pfizer
ATTR amyloidosis
tafamidis
Vyndaqel
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
CP Wire
Mon, 04/23/18 - 11:01 am
Alnylam
EMA
orphan drugs
ALN-TTRsc02
ATTR amyloidosis